Prospective Study for the Application of Cytosorb® in Critically Ill Patients

Prospective Quality Assurance Study for the Application of Cytosorb® in Patients With Cytokine Storm, Rhabdomyolysis and Acute Liver Failure

The mortality of critically ill patients is persistently high and requires targeted therapy of pathophysiological disorders. One approach to optimize therapy is the use of the cytokine adsorber Cytosorb®, which has a CE certification for the indications hyperinflammation, rhabdomyolysis and liver failure and is therefore frequently used in patients with sepsis, polytrauma and acute liver failure. Although few clinical data describe the efficiency mostly retrospectively, there are no data on real-time elimination performance and saturation kinetics during the course of treatment. These questions should be answered by the present study.

Inclusion Criteria:

• intensive care therapy
• hyperinflammation or acute liver dysfunction or rhabdomyolysis
• need of continuous renal replacement therapy
• treatment with Cytosorb (decision of the attending physician)

Exclusion Criteria:

- other reasons for Cytosorb application